Figure 4
Dose-response characterization of the influence of thalidomide, lenalidomide, pomalidomide, atRA, and SB431542 on LPM differentiation of XCL-1 clones. High content imaging analysis of XCL-1 hiPSC clones that were differentiated for 2 days in APEL2 + GSKi in the presence of compound and subsequently stained for FOXF1 and NANOG (only FOXF1 data shown here) and counter-stained with DAPI. Untreated DMSO control is represented as the lowest concentration in each graph. Data represent the mean +/− SEM %FOXF1+/DAPI+ cells from at least 4 independent experiments. Nonlinear regression analysis was performed using the 4-parameter [inhibitor] vs response variable slope plotting tool in GraphPad Prism. (A–E) Dose-response characterization of thalidomide (A), pomalidomide (B), lenalidomide (C), atRA (D), and SB431542 (E) in CRBN mock (hollow circles) or CRBN KO/KI (red filled circles) clones. (F–J) Dose-response characterization of thalidomide (F), pomalidomide (G), lenalidomide (H), atRA (I), and SB431542 (J) in SALL4 mock (hollow circles) and SALL4G416A (blue filled circles) clones.
